SCHEMBL1923925

SCHEMBL1923925

NC(=O)c1[nH]cc(CCC(=O)O)c1-c1ccc(NC(=O)Nc2ccc(OC(F)F)c(Cl)c2)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 12/20 0.50
MEN1 O00255 11/20 0.50
KMT2A Q03164 11/20 0.50
LMNA P02545 9/20 0.50
HTT P42858 8/20 0.50
SMN1; SMN2 Q16637 4/20 0.50
RAB9A P51151 2/20 0.50
NPSR1 Q6W5P4 2/20 0.50
GAA P10253 1/20 0.50
XBP1 P17861 1/20 0.50
CCR6 P51684 1/20 0.50
ALDH1A1 P00352 6/20 0.43
TP53 P04637 1/20 0.43
HTR1E P28566 1/20 0.43
S1PR3 Q99500 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
KDM4E B2RXH2 1/20 0.41
NPC1 O15118 1/20 0.40
NFKB1 P19838 1/20 0.40
NFKB2 Q00653 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1925482 0.86 STING1 (0.44) MAPTMEN1KMT2ALMNAHTT
SCHEMBL1924127 0.85 MAPT (0.52) MAPTMEN1KMT2ALMNAHTT
SCHEMBL1924361 0.83 KMT2A (0.46) MAPTMEN1KMT2ALMNAHTT
SCHEMBL1924893 0.81 KDR (0.51)
SCHEMBL1925173 0.80 MAPT (0.47) MAPTMEN1KMT2ALMNAHTT
SCHEMBL1924464 0.80 ALDH1A1 (0.38) MAPTMEN1KMT2AHTTSMN1; SMN2
SCHEMBL1925038 0.79 ROCK2 (0.46) MAPTMEN1KMT2ASMN1; SMN2RAB9A
SCHEMBL1924876 0.79 AKT2 (0.42) MEN1KMT2ASMN1; SMN2ALDH1A1POLB
SCHEMBL1923912 0.78 KDR (0.48) MAPTMEN1KMT2ASMN1; SMN2KDM4E
SCHEMBL1924884 0.78 MEN1 (0.42) MAPTMEN1KMT2ASMN1; SMN2TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1856043-B1 1-H-PYRROLE-2-CARBOXAMIDES AND IMIDAZOLE-5-CARBOXAMIDES AND USE THEREOF AS FAK, KDR AND TIE2 KINASE MODULATORS FOR THE TREATMENT OF CANCER AVENTIS PHARMA SA (FR) 2011-06-08 EP claimed